Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors.
Advanced breast cancer
CDK4/6 inhibitors
Skin adverse event
Vitiligo-like lesion
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
29
06
2020
accepted:
01
09
2020
pubmed:
12
9
2020
medline:
24
6
2021
entrez:
11
9
2020
Statut:
ppublish
Résumé
Introduction of cyclin-dependent inhibitors was a milestone in therapeutics for patients with estrogen receptor+/HER2- metastatic breast cancer. Despite the wide use of such agents and remarkable improvement of survival rates, drug-related adverse events are not yet fully characterized. We describe vitiligo-like lesions as a new adverse event occurring in patients with advanced breast cancer treated with cyclin-dependent inhibitors. We performed an international retrospective study including patients with advanced breast cancer who developed vitiligo-like lesions during treatment with cyclin-dependent kinases 4 and 6 inhibitors, in the period January 2018-December 2019. Patients > 18 years, both males and females, were recruited at six Dermatology Departments located in Italy (3), France (1) and Greece (2). We evaluated epidemiological and clinical characteristics, impact on quality of life and outcome of vitiligo-like lesions in patients treated with cyclin-dependent 4 and 6 inhibitors. The percentage of skin involved by vitiligo-like lesions was assessed using the Body Surface Area (BSA) score. Changes in patients' quality of life were investigated through the evaluation of the Dermatology Life Quality Index (DLQI) questionnaire. Sixteen women (median age: 62.5 years; range 40-79 years) treated with cyclin-dependent kinases 4 and 6 inhibitors for advanced breast cancer presented with vitiligo-like lesions during follow-up visits. Cutaneous lesions consisted of white, irregular macules and patches located mainly on sun-exposed areas in 11/16 patients or diffuse to the entire body surface in 5/16. Cutaneous lesions clearly impaired the quality of life of patients tested (DLQI ≥ 10). We present for the first time, to our knowledge, a case series of vitiligo-like lesions developing in patients with advanced breast cancer treated with cyclin-dependent kinases 4 and 6 inhibitors. We showed that such lesions further impair the patients' quality of life and their treatment is challenging.
Identifiants
pubmed: 32914354
doi: 10.1007/s10549-020-05914-w
pii: 10.1007/s10549-020-05914-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
247-253Références
Yan L, Rosen N, Arteaga C (2011) Targeted cancer therapies. Chin J Cancer 30(1):1–4. https://doi.org/10.5732/cjc.010.10553
doi: 10.5732/cjc.010.10553
pubmed: 21192839
pmcid: 4012258
Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135. https://doi.org/10.1056/NEJMoa1504627
doi: 10.1056/NEJMoa1504627
pubmed: 4681400
pmcid: 4681400
Gao JJ, Cheng J, Bloomquist E et al (2020) CDK 4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US food and drug administration pooled analysis. Lancet Oncol 21(2):250–260. https://doi.org/10.1016/S1470-2045(19)30804-6
doi: 10.1016/S1470-2045(19)30804-6
pubmed: 31859246
Choi YJ, Li X, Hydbring P et al (2012) The requirement for cyclin D function in tumor maintenance. Cancer Cell 22(4):438–451. https://doi.org/10.1016/j.ccr.2012.09.015
doi: 10.1016/j.ccr.2012.09.015
pubmed: 23079655
pmcid: 3487466
Hortobagyi GN, Stemmer SM, Burris HA et al (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375(18):1738–1748
doi: 10.1056/NEJMoa1609709
Tripathy D, Im SA, Colleoni M (2018) Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 19(7):904–915
doi: 10.1016/S1470-2045(18)30292-4
Im SA, Lu YS, Bardia A, Harbeck N et al (2019) Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 381(4):307–316
doi: 10.1056/NEJMoa1903765
Finn RS, Martin M, Rugo HS et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925–1936
doi: 10.1056/NEJMoa1607303
Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A (2020) Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 395(10226):817–827. https://doi.org/10.1016/S0140-6736(20)30165-3
doi: 10.1016/S0140-6736(20)30165-3
pubmed: 32145796
Saggar V, Wu S, Dickler MN, Lacouture ME (2013) Alopecia with endocrine therapies in patients with cancer. Oncologist 18(10):1126–1134. https://doi.org/10.1634/theoncologist.2013-0193
doi: 10.1634/theoncologist.2013-0193
pubmed: 24037977
pmcid: 3805155
Lasheen S, Shohdy KS, Kassem L, Abdel-Rahman O (2017) Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. Expert Rev Anticancer Ther 17(9):851–856. https://doi.org/10.1080/14737140.2017.1355242
doi: 10.1080/14737140.2017.1355242
pubmed: 28699811
Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE, Vitiligo Working Group (2017) New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol 77(1):1–13. https://doi.org/10.1016/j.jaad.2016.10.048
doi: 10.1016/j.jaad.2016.10.048
pubmed: 28619550
Zarogoulidis P, Huang H, Tsiouda T et al (2017) Immunotherapy “Shock” with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma. Respir Med Case Rep 26(22):283–286. https://doi.org/10.1016/j.rmcr.2017.10.006
doi: 10.1016/j.rmcr.2017.10.006
Dai J, Belum VR, Wu S, Sibaud V, Lacouture ME (2017) Pigmentary changes in patients treated with targeted anticancer agents: a systematic review and meta-analysis. J Am Acad Dermatol 77(5):902–910.e2. https://doi.org/10.1016/j.jaad.2017.06.044
doi: 10.1016/j.jaad.2017.06.044
pubmed: 28918974
pmcid: 5657394
Buchdunger E, Cioffi CL, Law N et al (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295(1):139–145
pubmed: 10991971
Mohammed GF, Gomaa AH, Al-Dhubaibi MS (2015) Highlights in pathogenesis of vitiligo. World J Clin Cases 3(3):221–230. https://doi.org/10.12998/wjcc.v3.i3.221
doi: 10.12998/wjcc.v3.i3.221
pubmed: 25789295
pmcid: 4360494
Boniface K, Dutriaux C, Prey S, Taieb A, Seneschal J (2018) Vitiligo-like lesions in patients receiving anti–programmed cell death-1 therapies are distinct from spontaneously occurring active vitiligo. J Am Acad Dermatol 78(1):e17–e18. https://doi.org/10.1016/j.jaad.2017.08.028
doi: 10.1016/j.jaad.2017.08.028
pubmed: 29241800
Zhou M, Lin F, Xu W, Jin R, Xu A (2018) Decreased SUMOylation of the retinoblastoma protein in keratinocytes during the pathogenesis of vitiligo. Mol Med Rep 18(3):3469–3475. https://doi.org/10.3892/mmr.2018.9299
doi: 10.3892/mmr.2018.9299
pubmed: 30066925
Thill M, Schmidt M (2018) Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol 3(10):1758835918793326. https://doi.org/10.1177/1758835918793326
doi: 10.1177/1758835918793326
Kim YJ, Cohen PR (2020) Anastrozole-induced dermatitis: report of a woman with an anastrozole-associated dermatosis and a review of aromatase inhibitor-related cutaneous adverse events. Dermatol Ther (Heidelb) 10(1):221–229. https://doi.org/10.1007/s13555-020-00353-3
doi: 10.1007/s13555-020-00353-3
Teulings HE, Limpens J, Jansen SN et al (2015) Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 33(7):773–781. https://doi.org/10.1200/JCO.2014.57.4756
doi: 10.1200/JCO.2014.57.4756
pubmed: 25605840
Hua C, Boussemart L, Mateus C et al (2016) Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152(1):45–51. https://doi.org/10.1001/jamadermatol.2015.2707
doi: 10.1001/jamadermatol.2015.2707
pubmed: 26501224